Atea Pharmaceuticals (AVIR) Change in Accured Expenses: 2018-2024
Historic Change in Accured Expenses for Atea Pharmaceuticals (AVIR) over the last 7 years, with Dec 2024 value amounting to -$13.4 million.
- Atea Pharmaceuticals' Change in Accured Expenses fell 85.98% to $1.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$37.6 million, marking a year-over-year decrease of 185.75%. This contributed to the annual value of -$13.4 million for FY2024, which is 206.00% down from last year.
- As of FY2024, Atea Pharmaceuticals' Change in Accured Expenses stood at -$13.4 million, which was down 206.00% from $12.7 million recorded in FY2023.
- Atea Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $43.9 million during FY2021, with a 5-year trough of -$37.6 million in FY2022.
- Over the past 3 years, Atea Pharmaceuticals' median Change in Accured Expenses value was -$13.4 million (recorded in 2024), while the average stood at -$12.8 million.
- Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 2,663.78% in 2020, then plummeted by 206.00% in 2024.
- Atea Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $12.4 million in 2020, then spiked by 252.79% to $43.9 million in 2021, then tumbled by 185.75% to -$37.6 million in 2022, then surged by 133.65% to $12.7 million in 2023, then tumbled by 206.00% to -$13.4 million in 2024.